Dyer, Gibb W. Jr., & Wilkins, Alan L. (1991). Better stories, not better constructs, to generate better theory: A rejoinder to Eisenhardt. Academy of Management Review, 16(3), 613-619.
Eisenhardt, Kathleen M. (1989). Building Theories from case study research. Academy of Management Review, 14(4), 532-550.
Gable, G.G. . (1994). Integrating Case Study and Survey Research Methods: An Example in Information Systems. European Journal of Information Systems, 3(2), 112-126.
LePine, Jeffery A., & Wilcox-King, Adelaide. (2010). Developing novel theoretical insight from reviews of existing theory and research. Academy of Management Review, 35(4), 506-509.
L. R. Yates et al., “Genomic Evolution of Breast Cancer Metastasis and Relapse,” Cancer Cell, vol. 32, no. 2, p. 169–184.e7, 2017.
A. D. Hartkopf et al., “Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry,” Breast, vol. 37, pp. 42–51, 2018.
H. Bartelink, “The changing landscape in radiotherapy for breast cancer: Lessons from long term follow-up in some European breast cancer trials,” Radiother. Oncol., vol. 121, no. 3, pp. 348–356, 2016.
M. Berlière et al., “The advantages of hypnosis intervention on breast cancer surgery and adjuvant therapy,” The Breast, vol. 37, pp. 114–118, 2018.
N. Arif and P. Ghezzi, “Quality of online information on breast cancer treatment options,” The Breast, vol. 37, pp. 6–12, 2018.
P. Poortmans, H. Marsiglia, M. De las Heras, and M. Algara, “Clinical and technological transition in breast cancer,” Reports Pract. Oncol. Radiother., vol. 18, no. 6, pp. 345–352, 2013.
J. Lester, “Local treatment of breast cancer,” Semin. Oncol. Nurs., vol. 31, no. 2, pp. 122–133, 2015.
M. L. Slattery et al., “Energy homeostasis genes and breast cancer risk: The influence of ancestry, body size, and menopausal status, the breast cancer health disparities study,” Cancer Epidemiol., vol. 39, no. 6, pp. 1113–1122, 2015.
P. E. Oguntunde, A. O. Adejumo, and H. I. Okagbue, “Breast cancer patients in Nigeria: Data exploration approach,” Data Br., vol. 15, pp. 47–57, 2017.
K. M. de Ligt, P. E. R. Spronk, A. C. M. van Bommel, M. T. F. D. Vrancken Peeters, S. Siesling, and C. H. Smorenburg, “Patients’ experiences with decisions on timing of chemotherapy for breast cancer,” Breast, vol. 37, pp. 99–106, 2018.
D. J. P. van Uden, H. W. M. van Laarhoven, A. H. Westenberg, J. H. W. de Wilt, and C. F. J. M. Blanken-Peeters, “Inflammatory breast cancer: An overview,” Crit. Rev. Oncol. Hematol., vol. 93, no. 2, pp. 116–126, 2015.
J. Cortés, S. A. Im, E. Holgado, J. M. Perez-Garcia, P. Schmid, and M. Chavez-MacGregor, “The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies,” Cancer Treat. Rev., vol. 61, pp. 53–60, 2017.
M. Makama et al., “An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®),” Eur. J. Cancer, vol. 75, pp. 5–13, 2017.
X. Tan, F. Camacho, V. D. Marshall, J. Donohoe, R. T. Anderson, and R. Balkrishnan, “Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer,” Res. Soc. Adm. Pharm., vol. 13, no. 4, pp. 796–810, 2017.
S. Lal, A. E. McCart Reed, X. M. de Luca, and P. T. Simpson, “Molecular signatures in breast cancer,” Methods, vol. 131, pp. 135–146, 2017.
A. Reginelli et al., “Management of breast cancer in elderly patients,” Int. J. Surg., vol. 12, no. S2, pp. S187–S192, 2014.
G. Rondanina, M. Puntoni, A. Guerrieri-Gonzaga, D. Marra, B. Bonanni, and A. DeCensi, “Worry and risk perception of breast cancer in a prevention trial of low dose tamoxifen in midlife postmenopausal hormone users,” Breast, vol. 34, pp. 108–114, 2017.
A. Falanga, L. Russo, V. Milesi, and A. Vignoli, “Mechanisms and risk factors of thrombosis in cancer,” Crit. Rev. Oncol. Hematol., vol. 118, no. June, pp. 79–83, 2017.
S. H. Ewaid and L. H. A. Al-Azzawi, “Breast cancer risk assessment by Gail Model in women of Baghdad,” Alexandria J. Med., vol. 53, no. 2, pp. 0–3, 2016.
J. Baselga, R. E. Coleman, J. Cortés, and W. Janni, “Advances in the management of HER2-positive early breast cancer,” Crit. Rev. Oncol. Hematol., vol. 119, no. July, pp. 113–122, 2017.
Z. Ghodsi, A. Salehi, and S. Hojjatoleslami, “Knowledge of Iranian Women about Warning Signs and Risk Factors for Breast Cancer,” Procedia - Soc. Behav. Sci., vol. 93, pp. 343–348, 2013.
M. C. Lauridsen, K. R. Tørsleff, H. Husted, and C. Erichsen, “Physiotherapy treatment of late symptoms following surgical treatment of breast cancer,” The Breast, vol. 9, no. 1, pp. 45–51, 2000.
C. Coleman, “Early Detection and Screening for Breast Cancer,” Semin. Oncol. Nurs., vol. 33, no. 2, pp. 141–155, 2017.
W. E. Barlow et al., “Performance of diagnostic mammography for women with signs or symptoms of breast cancer.,” J. Natl. Cancer Inst., vol. 94, no. 15, pp. 1151–9, 2002.
S. Keeney, H. McKenna, P. Fleming, and S. McIlfatrick, “An exploration of public knowledge of warning signs for cancer,” Eur. J. Oncol. Nurs., vol. 15, no. 1, pp. 31–37, 2011.
A. Mangla, N. Agarwal, F. Saei Hamedani, J. Liu, S. Gupta, and M. R. Mullane, “Metastasis of cervical cancer to breast: A case report and review of literature,” Gynecol. Oncol. Reports, vol. 21, no. June, pp. 48–52, 2017.
C. E. Champ et al., “Assessing Changes in the Activity Levels of Breast Cancer Patients During Radiation Therapy,” Clin. Breast Cancer, pp. 1–6, 2017.
V. Lope et al., “Physical activity and breast cancer risk by pathological subtype,” Gynecol. Oncol., vol. 144, no. 3, pp. 577–585, 2017.
A. Sonnenblick, N. Pondé, and M. Piccart, “Metastatic breast cancer: The Odyssey of personalization,” Mol. Oncol., vol. 10, no. 8, pp. 1147–1159, 2016.
C. Bohon, “Cancer Recognition and Screening for Common Breast Disorders and Malignancy,” Obstet. Gynecol. Clin. North Am., vol. 44, no. 2, pp. 257–270, 2017.
K. J. Ruddy et al., “Quality of life and symptoms in male breast cancer survivors,” The Breast, vol. 22, no. 2, pp. 197–199, 2013.
S. L. Savaridas, D. B. Taylor, D. Gunawardana, and M. Phillips, “Could parenchymal enhancement on contrast-enhanced spectral mammography (CESM) represent a new breast cancer risk factor? Correlation with known radiology risk factors,” Clin. Radiol., pp. 1–9, 2017.
A. C. P. Ribeiro Pereira, R. J. Koifman, and A. Bergmann, “Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up,” The Breast, vol. 36, pp. 67–73, 2017.
F. E. Lundberg, A. N. Iliadou, K. Rodriguez-Wallberg, C. Bergh, K. Gemzell-Danielsson, and A. L. V. Johansson, “Ovarian stimulation and risk of breast cancer in Swedish women,” Fertil. Steril., vol. 108, no. 1, pp. 137–144, 2017.
R. Glaser and C. Dimitrakakis, “Testosterone and breast cancer prevention,” Maturitas, vol. 82, no. 3, pp. 291–295, 2015.
M. Lambertini et al., “Fertility and pregnancy issues in BRCA-mutated breast cancer patients,” Cancer Treat. Rev., vol. 59, pp. 61–70, 2017.
C. a Gabriel and S. M. Domchek, “Breast cancer in young women.,” Breast Cancer Res., vol. 12, no. 5, p. 212, 2010.
C. Rousset-Jablonski and A. Gompel, “Screening for familial cancer risk: Focus on breast cancer,” Maturitas, no. August, pp. 0–1, 2017.
M. L. Peters, J. E. Garber, and N. Tung, “Managing hereditary breast cancer risk in women with and without ovarian cancer,” Gynecol. Oncol., vol. 146, no. 1, pp. 205–214, 2017.
S. Shmuel, A. J. White, and D. P. Sandler, “Residential exposure to vehicular traffic-related air pollution during childhood and breast cancer risk,” Environ. Res., vol. 159, no. June, pp. 257–263, 2017.
F. R. James, S. Wootton, A. Jackson, M. Wiseman, E. R. Copson, and R. I. Cutress, “Obesity in breast cancer - What is the risk factor?,” Eur. J. Cancer, vol. 51, no. 6, pp. 705–720, 2015.
D. Maliou and A. Bitam, “Implication of milk and dairy products consumption through insulin-like growth factor-I in induction of breast cancer risk factors in women,” Nutr. Clin. Metab., vol. 29, no. 4, pp. 219–225, 2015.
N. Y. Sofi et al., “Title: Reproductive factors, nutritional status and serum 25(OH)D levels in women with breast cancer: A case control study Reproductive factors, nutritional status and serum 25(OH)D levels in women with breast cancer: A case control study,” J. Steroid Biochem. Mol. Biol., vol. 25, 2017.
Z. Kleibl and V. N. Kristensen, “Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management,” The Breast, vol. 28, pp. 136–144, 2016.
F. MacNeill and A. Karakatsanis, “Over surgery in breast cancer,” The Breast, vol. 31, pp. 284–289, 2017.
C.-Y. Liu, C.-Y. Wu, K. Petrossian, T.-T. Huang, L.-M. Tseng, and S. Chen, “Treatment for the endocrine resistant breast cancer: Current options and future perspectives,” J. Steroid Biochem. Mol. Biol., vol. 172, no. July, pp. 166–175, 2017.
E. Folkerd and M. Dowsett, “Sex hormones and breast cancer risk and prognosis,” The Breast, vol. 22, pp. S38–S43, 2013.
A. Lee and M. Djamgoz, “Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies,” Manuscr. under Editor. Rev., 2017.
R. K. Charaghvandi, S. Yoo, B. van Asselen, A. Rodrigues, D. H. J. G. van den Bongard, and J. K. Horton, “Treatment constraints for single dose external beam preoperative partial breast irradiation in early-stage breast cancer,” Clin. Transl. Radiat. Oncol., vol. 6, pp. 7–14, 2017.
X. Zhou et al., “β-Glucosidase inhibition sensitizes breast cancer to chemotherapy,” Biomed. Pharmacother., vol. 91, pp. 504–509, 2017.
C. Y. Kuo, S. Y. Liang, S. L. Tsay, T. J. Wang, and S. F. Cheng, “Symptom management tasks and behaviors related to chemotherapy in Taiwanese outpatients with breast cancer,” Eur. J. Oncol. Nurs., vol. 19, no. 6, pp. 654–659, 2015.
C. Wang et al., “Triple negative breast cancer in Asia: An insider’s view,” Cancer Treat. Rev., vol. 62, pp. 29–38, 2018.
M. E. Cazzaniga, M. R. Dionisio, and F. Riva, “Metronomic chemotherapy for advanced breast cancer patients,” Cancer Lett., vol. 400, pp. 252–258, 2017.
M. Sibbering and C.-A. Courtney, “Management of breast cancer: basic principles,” Surg., vol. 34, no. 1, pp. 25–31, 2016.
S. A. Massarweh and G. L. Choi, “Special considerations in the evaluation and management of breast cancer in men,” Curr. Probl. Cancer, vol. 40, no. 2–4, pp. 163–171, 2016.
S. M. Rosenberg and A. H. Partridge, “Management of breast cancer in very young women,” Breast, vol. 24, pp. S154–S158, 2015.
A. De, G. Kuppusamy, and V. V. S. R. Karri, “Affibody molecules for molecular imaging and targeted drug delivery in the management of breast cancer,” Int. J. Biol. Macromol., 2017.
J. Cvetkovi?? and M. Nenadovi??, “Depression in breast cancer patients,” Psychiatry Res., vol. 240, pp. 343–347, 2016.
I. E. Smith and C. Fribbens, “Management of breast cancer in older and frail patients,” Breast, vol. 24, pp. S159–S162, 2015.
A. Nicolini, P. Ferrari, and M. J. Duffy, “Prognostic and predictive biomarkers in breast cancer: Past, present and future,” Semin. Cancer Biol., no. August, 2017.
T. Shen, C. Gao, K. Zhang, G. P. Siegal, and S. Wei, “Prognostic Outcomes in Advanced Breast Cancer: The Metastasis-free Interval is Important.,” Hum. Pathol., 2017.
A. Patil and G. V. Sherbet, “Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain,” Cancer Lett., vol. 358, no. 2, pp. 93–99, 2015.
Y. Wang, J. Zhou, Z. Wang, P. Wang, and S. Li, “Upregulation of SOX2 activated LncRNA PVT1 expression promotes breast cancer cell growth and invasion,” Biochem. Biophys. Res. Commun., vol. 493, no. 1, pp. 429–436, 2017.
C. Tsai, W. Su, J. Liang, H. Hsu, and W. Chen, “Original Article Glypican-3 Expression in Breast Cancer 原著論文 乳癌的 Glypican-3 之表現 Specimen Selection and Data Collection,” J. Cancer Res. Pract., vol. 2, no. 4, pp. 285–292, 2015.
F. H. Hsiao et al., “A longitudinal study of diurnal cortisol patterns and associated factors in breast cancer patients from the transition stage of the end of active cancer treatment to post-treatment survivorship,” Breast, vol. 36, pp. 96–101, 2017.
M. N. Liao et al., “Change and predictors of symptom distress in breast cancer patients following the first 4 months after diagnosis,” J. Formos. Med. Assoc., vol. 114, no. 3, pp. 246–253, 2015.
S. Doyle, J. Steel, and G. Porter, “Imaging male breast cancer,” Clin. Radiol., vol. 66, no. 11, pp. 1079–1085, 2011.
C. Rousset-Jablonski and A. Gompel, “Screening for familial cancer risk: Focus on breast cancer,” Maturitas, vol. 105, no. July, pp. 69–77, 2017.
W. Haven, “The Transition Experience to Breast Cancer Survivorship,” Semin. Oncol. Nurs., vol. 31, no. 2, pp. 178–182, 2015.
F. A. Peccatori, G. Codacci-Pisanelli, M. Del Grande, G. Scarfone, F. Zugni, and G. Petralia, “Whole body MRI for systemic staging of breast cancer in pregnant women,” Breast, vol. 35, pp. 177–181, 2017.
A. B. Chagpar, “On baseball and breast cancer,” Am. J. Surg., pp. 10–13, 2017.
A. H. Christian, D. O’Malley, A. Barac, S. M. Miller, and S. V. Hudson, “Cardiovascular risk and communication among early stage breast cancer survivors,” Patient Educ. Couns., vol. 100, no. 7, pp. 1360–1366, 2017.
S.-Q. Qiu et al., “Evolution in sentinel lymph node biopsy in breast cancer,” Crit. Rev. Oncol. Hematol., 2017.
T. Kim et al., “p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2,” J. Exp. Med., vol. 208, no. 5, pp. 875–883, 2011.
P. Dong et al., “Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis,” Oncogene, vol. 32, no. 27, pp. 3286–3295, 2013.
D. W. Cramer, A. F. Vitonis, K. L. Terry, W. R. Welch, and L. J. Titus, “The Association Between Talc Use and Ovarian Cancer,” Epidemiology, vol. 27, no. 3, pp. 334–346, 2016.
Barnard, M. E., Boeke, C. E., & Tamimi, R. M. (2015). Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochimica et Biophysica Acta - Reviews on Cancer, 1856(1), 73–85.
Davies, E. L. (2016). Breast cancer. Medicine, 44(1), 42–46.
Harbeck, N., & Gnant, M. (2017). Breast cancer. The Lancet, 389(10074), 1134–1150.
Jansen, L. A., Backstein, R. M., & Brown, M. H. (2014). Breast size and breast cancer: A systematic review. Journal of Plastic, Reconstructive & Aesthetic Surgery, 67(12), 1615–1623.
Kabel, A. M. (2017). Tumor markers of breast cancer: New prospectives. Journal of Oncological Sciences, 3(1), 5–11.
Klevos, G. A., Ezuddin, N. S., Vinyard, A., Ghaddar, T., Gort, T., Almuna, A., … Welsh, C. F. (2017). A Breast Cancer Review: Through the Eyes of the Doctor, Nurse, and Patient. Journal of Radiology Nursing, 36(3), 158–165.
Lope, V., Martín, M., Castelló, A., Casla, S., Ruiz, A., Baena-Cañada, J. M., … Pollán, M. (2017). Physical activity and breast cancer risk by pathological subtype. Gynecologic Oncology, 144(3), 577–585.
Mahvish Muzaffar, S. K. (2016). Impact of Primary Tumor Surgery in Stage IV Male Breast Cancer. Clinic Breast Cancer, 17(3), 1–7.
McNamara, K. M., Kannai, A., & Sasano, H. (2017). Possible roles for glucocorticoid signalling in breast cancer. Molecular and Cellular Endocrinology, 1–13.
Moira, L., Orsi, F., & Adam, A. (2017). Interventional radiology in breast cancer. The Breast, 35, 98–103.
Rodin, D., Knaul, F. M., Lui, T. Y., & Gospodarowicz, M. (2016). Radiotherapy for breast cancer: The predictable consequences of an unmet need. Breast, 29, 120–122.
Simapivapan, P., Boltong, A., & Hodge, A. (2016). To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review. Cancer Treatment Reviews, 50, 155–167.
Tang, Y., Wang, Y., Kiani, M. F., & Wang, B. (2016). Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. Clinical Breast Cancer, 16(5), 335–343.
Xiao, Q., Signorello, L. B., Brinton, L. A., Cohen, S. S., Blot, W. J., & Matthews, C. E. (2016). Sleep duration and breast cancer risk among black and white women. Sleep Medicine, 20, 25–29.
Pudkasam, S., Tangalakis, K., Chinlumprasert, N., Apostolopoulos, V., & Stojanovska, L. (2017). Breast cancer and exercise: The role of adiposity and immune markers. Maturitas, (April), 0–1.
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
Submission of the manuscript represents that the manuscript has not been published previously and is not considered for publication elsewhere.